Clinical trials: Epithelial Cancer Patients
High Grade Glioma
Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma
A Phase 1 Multi-center clinical Trial Evaluating the Safety and Tolerability of 5-aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With recurrent High Grade Glioma…
- Trial name
- NCT05362409
- Testing
- 5 Aminolevulinic Acid, CV01-delivered ultrasound
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Alpheus Medical, Inc.
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma
Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma
This randomized phase III trial is studying cyclophosphamide, prednisone, and immunoglobulin to see how well they work compared to cyclophosphamide and prednisone alone in treating patients with abnormal trunk muscle movements…
- Conditions
- Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma
- Trial name
- NCT00033293
- Testing
- Clinical Observation, Cyclophosphamide, Laboratory Biomarker Analysis
- Where
- 104 sites in United States, Australia and 1 more
- Volunteers
- 53 people
- Sponsor
- Children's Oncology Group
Basal Cell Carcinoma, Squamous Cell Carcinoma
Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery
Midazolam is an approved sedative medication used for medical procedures. This study was being done to document the safety and efficacy of midazolam in improving anxiety, heart rate, and blood pressure in patients prior to…
- Conditions
- Basal Cell Carcinoma, Squamous Cell Carcinoma, Skin Cancer, Anxiety
- Trial name
- NCT00578214
- Testing
- Randomized Midazolam, Local Anesthesia, Prospective Midazolam
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Mayo Clinic
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Squamous Cell Carcinoma, Oral Cancer
Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC
In this study, 100 patients with resectable head and neck squamous cell carcinoma (oral squamous cell carcinoma and oropharyngeal squamous cell carcinoma) were enrolled, who were combined with tirelizumab, carboplatin and…
- Trial name
- HNC-SYSU-001 (NCT05941338)
- Testing
- Tirelizumab ,+Carboplatin+albumin-bound paclitaxel
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Radiation Therapy During Surgery in Treating Older Women With Invasive Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation during surgery may be an effective treatment for breast cancer.
- Trial name
- NRR (NCT00182728)
- Testing
- surgery, therapy, radiation therapy
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Insular Thyroid Cancer, Recurrent Thyroid Cancer
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
This phase II trial is studying how well bortezomib works in treating patients with metastatic thyroid cancer that did not respond to radioactive iodine therapy.
- Conditions
- Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer
- Trial name
- NCT00104871
- Testing
- Bortezomib
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
HRD-negative Epithelial Ovarian Cancer
A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer
This is a single-center, open-label, dose-escalation, multiple-dose investigator-initiated exploratory study designed to evaluate the safety, tolerability and preliminary efficacy of tumor neoantigen-pulsed autologous dendritic…
- Trial name
- YS247 (NCT07455071)
- Testing
- Tumor Neoantigen-Sensitized Autologous Dendritic Cell Injection (YS247)
- Volunteers
- 9 people
- Sponsor
- Peking University Third Hospital
Brain and Central Nervous System Tumors
Talampanel in Treating Patients With Recurrent High-Grade Glioma
RATIONALE: Drugs used in chemotherapy such as talampanel use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00064363
- Testing
- talampanel
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This phase II trial studies the side effects and how well EGEN-001 works in treating patients with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer that is persistent or has come back.
- Conditions
- Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT01118052
- Testing
- Laboratory Biomarker Analysis, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1
- Where
- 11 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gynecologic Oncology Group
Oral Squamous Cell Carcinoma (OSCC)
A Dye for the Detection of Cancer of the Tongue and Mouth
The purpose of this study is to test if an investigational dye, called PARPi-FL, can be used to detect this type of cancer. This will be the first time that PARPi-FL is being tried in people.
- Trial name
- NCT03085147
- Testing
- Olaparib
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Epithelial Ovarian Cancer
Effect of Early Enteral Nutrition on Postoperative Recovery of Ovarian Cancer Patients
This is a single-center, unblinded, prospective observational study, and the objective is to compare the effects of enteral nutrition via nasojejunal tube and parenteral nutrition via vein on patients' early recovery and…
- Trial name
- NCT06236958
- Testing
- Transnasal jejunal tube, Transvenous access
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Luo Chengyan
Renal Cell Cancer
An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell Carcinoma
This observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with interferon alpha-2a as first-line treatment in patients with advanced and/or metastatic renal cell carcinoma.
- Trial name
- NCT01351571
- Where
- 2 sites in India
- Volunteers
- 5 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma (HCC)
A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma
This investigational study will evaluate if using a combination of TACE along with high dose SBRT would show improvement in local control in patients with Hepatocellular Carcinoma.
- Trial name
- RAD 0902 (NCT01247298)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Alabama at Birmingham
Neuroblastoma
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
This is a phase II single center study to administer two courses of myeloablative consolidation chemotherapy each followed by an autologous peripheral blood stem cell (PBSC) rescue in patients with high-risk neuroblastoma who…
- Trial name
- NCT02605421
- Testing
- Thiotepa, Cyclophosphamide, Melphalan
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Infiltrating Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
This pilot clinical trial studies the side effects of recombinant EphB4-HSA fusion protein before surgery in treating patients with transitional cell carcinoma of the bladder, prostate cancer, or kidney cancer.
- Conditions
- Infiltrating Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma, Stage I Prostate Cancer, Stage I Renal Cell Cancer
- Trial name
- NCT02767921
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Radical Cystectomy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Southern California
Squamous Cell Carcinoma of Head and Neck
SHR-1701 in Patients With Recurrent/Metastatic Scchn
This is an open label, single-arm, multi-center, phase II study of SHR-1701 in patients with recurrent/metastatic SCCHN
- Trial name
- NCT04650633
- Testing
- SHR-1701
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Cholangiocarcinoma
Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations
The purpose of this study is to determine the rate of progression free survival of patients with inoperable cholangiocarcinoma 6 months after enrollment in the study.
- Trial name
- GOC-B-P (NCT01206049)
- Testing
- Gemcitabine, Oxaliplatin, Capecitabine
- Where
- Denmark
- Volunteers
- 88 people
- Sponsor
- Vejle Hospital
Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell
Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent /…
- Conditions
- Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors
- Trial name
- STAR-TOR (NCT00700258)
- Testing
- Temsirolimus, Sunitinib, Axitinib
- Where
- 77 sites in Germany
- Volunteers
- 1,520 people
- Sponsor
- Pfizer
Carcinoma, Renal Cell
CPG 7909 in Patients Wih Stage IV Renal Cell Cancer
CPG 7909 given alone to patients with renal cell cancer after their nephrectomy. CPG 7909 is as a subcutaneous injection once per week for up to 24 weeks. Up to 40 patients will be included in the study.
- Trial name
- NCT00043407
- Testing
- CPG 7909
- Volunteers
- 42 people
- Sponsor
- Pfizer